INDBInternet News Database 2.5 Updated 2 min ago · 292 sources Show or hide images Light or dark

M1/M4 Agonist Relieved Schizophrenia Symptoms in Mid-Stage Trial

1 source1 article First seen Updated United States Truth score 38

Save Like Comments Compare coverage
Image from Medpagetoday

Summary

(MedPage Today) -- ML-007C-MA, an investigational muscarinic M1/M4 receptor agonist that combines betovumeline and fesoterodine fumarate, significantly improved schizophrenia symptoms in adults who had an acute exacerbation of psychosis, data from...

Description from Medpagetoday.

Who is covering this

  1. Medpagetoday Center Factuality: Mostly factual US
    M1/M4 Agonist Relieved Schizophrenia Symptoms in Mid-Stage Trial

    (MedPage Today) -- ML-007C-MA, an investigational muscarinic M1/M4 receptor agonist that combines betovumeline and fesoterodine fumarate, significantly improved schizophrenia symptoms in adults who had an acute exacerbation of psychosis, data from...

Comments

Comments need JavaScript.